Heparinase-producing <i>Pseudomonas stutzeri </i>strain and heparinase derived therefrom

Abstract

The invention relates to the field of bioengineering. In particular, the invention relates to a heparinase-producing Pseudomonas stutzeri strain and a heparinase derived therefrom. Furthermore, the invention relates to the preparation and use of the heparinase.

Claims

1. A recombinant heparinase comprising an amino acid sequence shown in SEQ ID NO:2, wherein the recombinant heparinase comprises a linker or is fused to a tag, wherein the linker and/or tag facilitates the production of the recombinant heparinase in a host cell of interest, increases the amount of expression or increases the soluble expression, facilitates the isolation and purification of the recombinant heparinase, but do not substantially affect the activity of the recombinant heparinase.

2. An expression construct, comprising a nucleotide sequence encoding the heparinase comprising an amino acid sequence shown in SEQ ID NO:2, operably linked to an expression control sequence.

3. A recombinant host cell, which is transformed with the expression construct of claim 2.

4. A method for producing a heparinase, comprising: a) culturing the host cell of claim 3 under a condition that allows the expression of the heparinase; b) obtaining the heparinase expressed by the host cell from the culture obtained from step a); and c) optionally further purifying the heparinase obtained from step b).

5. A method for producing heparinase which comprises: culturing a Pseudomonas stutzeri strain deposited at the China Center for Type Culture Collection under the Accession Number CCTCC M 2017174; lysing the cultured cells of the Pseudomonas stutzeri strain; and isolating and/or purifying the heparinase from the lysate.

6. A method for producing heparinase, wherein the method comprises the steps of: a) culturing a Pseudomonas stutzeri strain deposited at the China Center for Type Culture Collection under the Accession Number CCTCC M 2017174 and collecting the cultured bacterial cells; b) resuspending and lysing the cells obtained in step a) in a buffer, and collecting the supernatant after centrifugation; c) precipitating the supernatant obtained in step b) with ammonium sulfate of 20% to 100% saturation, and dissolving the resulting precipitate in a buffer and dialyzing against the buffer; d) loading the product of step c) onto an anion exchange column, equilibrating the column with a buffer, and collecting the loading flow-through and the equilibrating flow-through, and dialyzing the collected loading flow-through and the equilibrating flow-through against the buffer; e) loading the product of step d) onto a cation exchange column, and equilibrating the column with a buffer, performing linear gradient elution with a sodium chloride solution based on the same buffer, collecting fractions of the eluate with heparinase activity, and optionally dialyzing the collected eluate against the buffer.

7. The method of claim 6, wherein the method further comprises the steps of: f) loading the product of step e) onto a heparinase affinity column, and equilibrating the column with a buffer, performing linear gradient elution with a sodium chloride solution based on the same buffer, collecting fractions of the eluate with heparinase activity, and optionally dialyzing the collected eluate against the buffer.

8. The method of claim 7, wherein the heparinase affinity column is selected from a Cellufine Sulfate column and a heparin-conjugated CNBr-activated Sepharose CL-4B heparinase affinity column; and the sodium chloride solution is a 0.15-0.6M sodium chloride solution.

9. The method of claim 6, wherein the anion exchange column is selected from Q-Sepharose Fast Flow, Q-Sepharose Big Beads, Q-Sepharose XL and Q-Sepharose High Performance columns; the cation exchange column is a SP-Sepharose Fast Flow column; and the sodium chloride solution is a 0-0.5M sodium chloride solution.

10. The method of claim 6, wherein the heparinase has one or more characteristics selected from the group consisting of: i) a molecular weight of 74791 Da; ii) an isoelectric point of 7.77; iii) a HEP/HS enzyme activity ratio of 0.87:1 with heparin (HEP) and HS (heparan sulfate) as the substrates; iv) a Michaelis constant of 4.20 with HEP as the substrate; v) a Michaelis constant of 0.28 with HS as the substrate; and vi) when HEP is used as the substrate, the major heparin disaccharide products are IIS and IS.

11. A method for producing heparinase, wherein the method comprises the steps of: a) culturing a Pseudomonas stutzeri strain deposited at the China Center for Type Culture Collection under the Accession Number CCTCC M 2017174 and collecting the cultured bacterial cells; b) resuspending and lysing the cells obtained in step a) in a buffer and collecting the supernatant after centrifugation; c) precipitating the supernatant obtained in step b) with ammonium sulfate of 20% to 100% saturation, and dissolving the resulting precipitate in a buffer and dialyzing against the buffer; d) loading the product of step c) onto an anion exchange column, and equilibrating the column with a buffer, performing linear gradient elution with a sodium chloride solution based on the same buffer, collecting fractions of the eluate with heparinase activity, and optionally dialyzing the collected eluate against the buffer.

12. The method of claim 11, wherein the method further comprises the steps of: e) loading the product of step d) onto a heparinase affinity column, and equilibrating the column with a buffer, performing linear gradient elution with a sodium chloride solution based on the same buffer, collecting fractions of the eluate with heparinase activity, and dialyzing the collected eluate against the buffer; f) loading the product of step e) onto a heparinase affinity column, and equilibrating the column with a buffer, performing isocratic elution with a sodium chloride solution based on the same buffer, and collecting fractions of the eluate with heparinase activity; and g) loading the product of step f) onto a heparinase affinity column, and equilibrating the column with a buffer, performing linear gradient elution with a sodium chloride solution based on the same buffer, collecting fractions of the eluate with heparinase activity, and optionally dialyzing the collected eluate against the buffer.

13. The method of claim 12, wherein the heparinase affinity column is a Cellufine Sulfate column; the sodium chloride solution in step e) is a 0.05-0.5M sodium chloride solution; the sodium chloride solution in step f) is a 2.5M sodium chloride solution; and the sodium chloride solution in step g) is a 0-0.5M sodium chloride solution.

14. The method of claim 11, wherein the anion exchange column is selected from Q-Sepharose Fast Flow, Q-Sepharose Big Beads, Q-Sepharose XL and Q-Sepharose High Performance columns; and the sodium chloride solution is a 0-0.5M sodium chloride solution.

15. The method of claim 11, wherein the heparinase has one or more characteristics selected from the group consisting of: i) a molecular weight of 94716 Da; ii) an isoelectric point of 5.76; iii) a HEP/HS enzyme activity ratio of 1:4.3 with heparin (HEP) and HS (heparan sulfate) as the substrates; iv) a Michaelis constant of 0.09 with HEP as the substrate; and v) a Michaelis constant of 0.25 with HS as the substrate.

16. A method for producing a low molecular weight heparin or an ultra-low molecular weight heparin, comprising the step of contacting the heparin with the heparinase obtained by the method of claim 5, 6 or 11.

17. A method for producing a low molecular weight heparin or an ultra-low molecular weight heparin, comprising the step of contacting the heparin with the recombinant heparinase comprising an amino acid sequence shown in SEQ ID NO:2.

18. A method for producing a low molecular weight heparin or an ultra-low molecular weight heparin, comprising the step of contacting the heparin with the host cell of claim 3.

Description

DESCRIPTION OF DRAWINGS

(1) FIG. 1 shows a SDS-PAGE image of the purified PShepI, PShepII.

(2) FIG. 2 is a liquid chromatographic image of the enzymolysis product of HEP by PShepI.

EXAMPLES

(3) The invention is further described below by examples, but is not intended to be limited to such examples.

(4) In the examples of the present application, the enzyme activity for the heparin (HEP) and the heparin sulfate (HS) is determined by reference to Chinese Patent Application No. 201110241260.4. Methods for determining the protein content and the enzyme purity are described in Carbohydrate Research, 2012, 359: 37-43.

(5) Method for detecting the desulfurase: 52 mIU heparinase was used to react with 10 l of 1 mg/ml I-S, and 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, with pH of 7.0) buffer was added to bring the reaction system to 200 l. The reaction was performed at room temperature for 24 hours, and heparinase was inactivated by boiling in a 100 C. water bath for 5 min, and loaded onto a HPLC-SAX column to determine the relative percentage of II-S and I-S.

Example 1: Isolation and Identification of a New Pseudomonas stutzeri Strain

(6) Screening of Heparinase-Producing Strains

(7) Soil samples were collected from the west of Chengguan Town, Yunmeng County, Hubei Province, China; heparin was dissolved in purified water (less than or equal to 8 g/L), poured into each soil sample to keep each soil sample moist. The samples were so treated once to twice a week (the frequency depending on the dryness of the soil sample), and cultured for 35-40 days. Two spoons of soil samples were taken with a weighing spoon and added to autoclaved purified water, and shook (150 rpm) for 2-3 hours in a shaker at 30 C. to allow the soil samples uniformly distributed in the purified water. 20 ml of the purified water with the dissolved soil sample was pipetted into 200 ml autoclaved seed culture medium, shook at 30 C. in a shaker for 16 hours (150 rpm), and then 2.5 ml bacteria liquid was pipetted into a 4 ml quartz cuvette to test its OD600 to determine the growth of the strain. If the OD600 of the strain in the previous step is greater than 2.4, then 20 ml bacteria liquid was pipetted into 200 ml of autoclaved fermentation medium, shook at 30 C. for 24 hours in a shaker (150 rpm), and then 3 ml of the bacteria liquid was pipetted as a sample.

(8) 2.5 ml bacteria liquid was pipetted from the 3 ml bacteria liquid sample and added to a 4 ml quartz cuvette to detect its OD600 to determine the growth of the strain. If the OD600 of the strain is greater than 2.0, it means the strain grows well in the fermentation medium. At the same time, the remaining 0.5 ml bacteria liquid was centrifuged (4 C., 5000 g, 5 min) to obtain a supernatant, and the supernatant was then diluted by 10 times with ultrapure water for use. Heparin was dissolved in ultrapure water and diluted to 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml. 2.5 ml of Azure A solution (20 mg/L) and 25 l of the heparin aqueous solution were added into a cuvette and mixed to detect the absorption value at 620 nm, and then a standard curve was plotted. After that, the absorption value of the diluted strain supernatant at 620 nm was detected in the same manner, and the heparin concentration was calculated. If the heparin concentration is less than 5.5 g/L, it is considered that the bacteria liquid contains a strain capable of consuming heparin (heparinase-producing). The bacterial liquid resulting in a heparin concentration of less than 5.5 g/L was diluted and plated (10e-6, 10e-7, 10e-8, 10e-9), and after about 3-4 days, colonies or microbial population were observed on the surface of the solid medium. A plurality of colonies were picked up from the surface of the medium in the previous step to carry out plate streaking, and after 2-3 days of culture, relatively pure single colonies were selected.

(9) The colonies obtained by plate streaking were scraped off and added to the seed medium and cultured for 16 hours, and then transferred to a fermentation medium (10% inoculum) for about 24 hours. A sample was taken from the fermentation medium, and its heparin consumption was detected by referring to the aforementioned steps. If the heparin consumption is still less than 5.5 g/L, then the steps of diluting and coating and plate streaking were repeated for further purifying the strain until a pure single colony is obtained. The re-screening can be carried out several times according to the purity of the colony. In this experiment, all the soil samples with desired activity were screened 3 times.

(10) Single colonies were streaked on a slant medium and stored in a liquid medium. The streaked slant medium was stored in a cold storage, and the cultured bacteria liquid was stored in a 50% glycerin and stored in a refrigerator at 20 C.

(11) Identification of Heparinase-Producing Strains

(12) The heparinase-producing strain was purified to a pure single colony, and then sent to the Guangdong Provincial Microbial Analysis and Testing Center for identification.

(13) Through bacterial microscopic observation, physical and chemical property analysis and 16S rDNA sequence alignment, it was confirmed that the present inventors screened out a Pseudomonas stutzeri strain capable of producing heparinase, which was named as Z7. The strain was deposited at the China Center for Type Culture Collection (Wuhan University, Wuhan, China, 430072) on Apr. 10, 2017 under the Budapest Treaty under the accession number: CCTCC M 2017174, and it is confirmed that: (a) during the pendency of this application, access to the deposited organism will be afforded to the Commissioner upon request; (b) all restrictions upon availability to the public of the deposited materials will be irrevocably removed upon granting of the patent, subject to 37 C.F.R., 1.808(b); (c) the deposit will be maintained for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer; and (d) the deposit will be replaced if it should ever become non-viable.

(14) It is known that Pseudomonas stutzerii is basically non-pathogenic to human and can degrade carrageenan. It is a bacterium effective for sewage treatment and soil waste treatment, and is a denitrifying bacteria with the ability to corrode metals. However, there have been no reports on the ability of Pseudomonas stutzeri to produce heparinase.

(15) Identification of Heparinase Activity of Z7 Strain

(16) The identified Z7 strain with the desired enzyme activity was fermented, and the activity for HEP and HS was measured after cell disruption (1 L fermented cells). The results are shown in

(17) TABLE-US-00001 TABLE 1 HEP and HS activity measured after fermentation and cell disruption of Z7 strain HEP enzyme HS enzyme activity (IU/L) activity (IU/L) 592.2 602.1

Example 2: Preparation of Heparinase from Z7 Strain and Activity Determination

(18) Preparation of the Medium:

(19) The formula of the seed medium: beef extract 5 g/L, peptone 10 g/L, yeast powder 5 g/L, sodium chloride 5 g/L, pH7.0; the formula of the fermentation medium: heparin 8 g/L, peptone 2 g/L, potassium dihydrogen phosphate 2.5 g/L, ammonium sulfate 1 g/L, magnesium sulfate 0.5 g/L, sodium chloride 5 g/L, pH 7.0; the solid medium is prepared by adding 20 g/L agar powder to the fermentation medium.

(20) Fermentation of Strains and Preparation of Crude Enzyme Solution:

(21) The Z7 Pseudomonas stutzeri strain was inoculated into the seed culture medium by scraping two rings of bacteria from the plate or the slant. After 16 hours of culture, the seed was added to a secondary liquid seed culture medium with a 15% inoculation amount, cultured for 1 day, and then inoculated into a 2 L fermentation medium with a 20% inoculation amount, cultured for 1 day. The bacteria cells were collected by centrifuging at 3800 rpm, 4 C. for 45 minutes, and then the precipitate was suspended in a 25 mM Tris-HCl buffer (containing 10 mM CaCl.sub.2, pH 7.0), lysed by a high pressure homogenizer at 4 C., 800 bar for 3-4 cycles, and centrifuged for 30 minutes (12000 rpm, 4 C.). The supernatant was precipitated with ammonium sulfate in an ice bath, and precipitate at 20%-100% ammonium sulfate saturation was collected and dissolved in 100 ml Tris-HCl buffer, and dialyzed overnight against the same buffer.

(22) Preparation Method I

(23) Q-Sepharose Fast Flow column separation: The dialyzed crude enzyme solution after the previous step was loaded onto a 2.530 cm Q column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer. The column was equilibrated with 3 column volumes of the same buffer and eluted with a linear gradient of a buffer containing 0-0.5 M sodium chloride. One peak with desired activity was obtained, designated as PShepII. The loading flow-through and the equilibrating flow-through were detected and found to have heparinase activity, and the enzyme solution of this part was named as PShepI. The PShepI and PShepII fractions were collected and dialyzed against 2 L 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer overnight.

(24) Purification of PShepI by Cellufine Sulfate Column I: The dialyzed PShepI-containing enzyme solution was applied to a CS column (2.530 cm) and equilibrated with 3 column volumes of a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer. The column was then eluted with a gradient of the same buffer containing 0-1 M sodium chloride. The fractions with enzyme activity were detected and dialyzed against 2 L of 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer overnight.

(25) Purification of PShepI by Cellufine Sulfate Column II: The dialyzed enzyme solution after the previous step was taken out and loaded onto a well-equilibrated CS column of the same size. The column was equilibrated with 3 column volumes of a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer containing 0.15 M sodium chloride, and then eluted with a gradient of the same buffer containing 0.15-0.6 M sodium chloride. The fractions with enzyme activity were detected and dialyzed overnight.

(26) Purification of PShepI by SP Column: The dialyzed enzyme solution after the previous step was loaded to a well-equilibrated SP column (specification: 2.530 cm). The column was then equilibrated with 3 column volumes of a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer, and then eluted with a gradient of the same buffer containing 0-0.5M sodium chloride. The heparinase activity was detected. Detection of an undesired enzyme which can remove the sulphate from carbohydrate chain was carried out for single fractions with enzyme activity, the fractions with no such reactions and with IIS content of less than 1% after heparin treatment were collected, which has basically no impurity band. Finally, the products were concentrated in a 30K ultrafiltration centrifuge tube. The concentrated enzyme is PShepI enzyme with high-purity. The concentrated enzyme is made up to 0.5 ml with the corresponding buffer and mixed with glycerol in a 1:1 ratio and stored in a refrigerator at 20 C.

(27) Purification of PShepII by Gradient Elution with Cellufine Sulfate Column I: The dialyzed PShepII fractions were loaded onto a 2.530 cm CS column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer. The column was equilibrated with 3 column volumes of the buffer containing 0.05 M sodium chloride and then eluted with a linear gradient of the same buffer containing 0.05-0.5 M sodium chloride. The fractions with enzyme activity were collected and dialyzed using 2 L 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer overnight.

(28) Purification of PShepII by Isocratic Elution with Cellufine Sulfate Column II: The dialyzed PShepII fractions after the previous step were loaded onto a 2.530 cm CS column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl 2, pH 7.0) buffer. The column was then equilibrated with 3 column volumes of the same buffer. The fractions with enzyme activity were then collected by isocratic elution with the same buffer containing 0.25 M sodium chloride.

(29) Concentration of PShepII by Cellufine Sulfate Column III: The active PShepII fractions after isocratic elution in the previous step were added to 1 volume of 25 mM Tris-HCl (containing 10 mM CaCl.sub.2), pH 7.0) buffer and loaded onto an equilibrated 2.530 cm CS column. The column was equilibrated with 3 column volumes of the same buffer, and then eluted with a gradient of the same buffer containing 0-0.5 M sodium chloride. The fractions with enzyme activity were separately subjected to a detection of undesired enzyme which can remove the sulphate from carbohydrate chain. The fractions with no undesired enzyme reactions and with IIS content of less than 1% after heparin treatment were collected, which is the new enzyme PShepII with high-purity. SDS-PAGE was performed to confirm that it is the basically free of impurity band. The high-purity PShepII was concentrated using a 30 KD ultrafiltration centrifuge tube, and mixed with 1 volume of glycerol and stored in a refrigerator at 20 C.

(30) The enzyme activity, protein content, (specific activity) purification ratio, and (total activity) yield of PShepI and PShepII after each step are shown in Table 2 and Table 3, respectively.

(31) TABLE-US-00002 TABLE 2 Enzyme activity and protein content of each step of PShepI purification by Method I PShepI HEP Puri- puri- Total Total enzyme Total Specific fi- fication volume protein activity activity activity cation Yield step (ml) (mg) (IU/ml) (IU) (IU/mg) ratio (%) Crude 461.00 231.71 0.48 220.12 0.95 / / enzyme Ammo- 415.00 144.93 0.51 211.60 1.46 1.54 96.13 nium sulfate precipi- tation Q 75.00 10.53 0.76 56.00 5.32 5.60 25.44 Column CS-I 30.00 3.88 1.35 40.50 10.45 11.00 18.41 Column CS-II 45.00 2.18 0.65 29.00 13.31 30.53 13.17 Column SP 1.00 0.50 12.80 12.80 25.60 26.95 5.81 Column

(32) TABLE-US-00003 TABLE 3 Enzyme activity and protein content of each step of PShepII purification by Method I HEP en- zyme Spe- PShepII ac- Total cific Puri- Puri- Total Total tivity ac- activity fi- fication volume protein (IU/ tivity (IU/ cation Yield step (ml) (mg) ml) (IU) mg) ratio (%) Crude 461.00 231.71 0.48 220.12 0.95 / / enzyme Ammo- 415.00 144.93 0.51 211.6 1.46 1.54 96.13 nium sulfate precipi- tation Q 99.00 18.11 0.45 40.00 2.21 2.33 18.17 Column CS-I 31.00 3.88 0.52 16.00 4.12 4.34 7.27 Column CS-II 22.00 1.94 0.64 14.00 7.20 7.58 6.36 Column Sephadex 1.00 0.46 8.20 8.20 18.00 18.95 3.73 G-100
Preparation Method II

(33) Q-Sepharose Fast Flow column separation: The dialyzed crude enzyme solution prepared by the above ammonium sulfate precipitation was loaded onto a standard 2.530 cm Q-Sepharose Fast Flow column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer, and the column was equilibrated with 3 column volumes of the same buffer. A linear gradient elution with 0-1 M sodium chloride in the same buffer was performed. Fractions with enzyme activity were detected, labeled as PShepII, collected and dialyzed with 2 L 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer overnight. The loading flow-through and the equilibrating flow-through were detected, and the fractions with enzyme activity were collected and labeled as PShepI.

(34) Purification of PShepI by SP column: The PShepI-containing enzyme solution obtained in the previous step was loaded onto a 2.530 cm SP-Sepharose Fast Flow equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer. The column was equilibrated with 3 column volumes of the same buffer and then eluted with a linear gradient of the same buffer containing 0-0.5 M sodium chloride. The active fractions were collected and dialyzed against 2 L of 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer overnight.

(35) Purification of PShepI by Cellufine Sulfate column: The enzyme solution obtained in the previous step was loaded onto a 2.530 cm Cellufine Sulfate column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer, and the column was then equilibrated with 3 column volumes of the same buffer containing 0.15 M sodium chloride, and then eluted with a linear gradient of the same buffer containing 0.15-0.6 M sodium chloride. The active fractions were collected, pooled, and concentrated through ultrafiltration to 1 mL by a 30 kD ultrafiltration centrifuge tube.

(36) Purification of PShepII by linear gradient elution with Cellufine Sulfate-I: The dialyzed enzyme solution separated by Q column was loaded onto a standard 2.530 cm Cellufine Sulfate column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer, and the column was then equilibrated with the same buffer containing 0.05 M sodium chloride, provided with gradient elution with a buffer containing 0.05-0.5 M sodium chloride. The active fractions were collected and dialyzed against a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer overnight.

(37) Purification of PShepII by isocratic elution with Cellulide Sulfate-II column: The dialyzed enzyme solution from the previous step was loaded again onto a standard 2.530 cm Cellufine Sulfate column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer, and then isocraticaly eluted with 800 ml of the same buffer containing 0.25 M sodium chloride. The active fractions were then collected.

(38) Cellufine Sulfate-III column concentration: One volume of 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer was added to the active PShepII solution after isocratic elution, and loaded onto a 2.530 cm CS column equilibrated with a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer. The column was equilibrated with the same buffer, and then eluted with a linear gradient of the same buffer containing 0-0.5 M sodium chloride. The active fractions were collected, pooled and concentrated to 1 mL by ultrafiltration using a 30 kD ultrafiltration centrifuge tube.

(39) The enzyme activity and protein content obtained in each step of the purification process are shown in Tables 4 and 5 below:

(40) TABLE-US-00004 TABLE 4 Enzyme activity and protein content of each step of PShepI purification in Method II PShepI HEP Puri- puri- Total Total enzyme Total Specific fi- fication volume protein activity activity activity cation Yield step (ml) (mg) (IU/ml) (IU) (IU/mg) ratio (%) Crude 461.00 231.71 0.48 220.12 0.95 / / enzyme Precipi- 415.00 144.93 0.51 211.60 1.46 1.54 96.13 tation of ammo- nium sulfate Q 115.08 41.66 1.18 135.80 3.26 3.43 61.69 Column SP 54.00 9.49 1.91 103.14 10.87 11.44 46.86 Column CS 1.00 1.35 57.70 57.70 42.70 44.95 26.21 Column

(41) TABLE-US-00005 TABLE 5 Enzyme activity and protein content of each step of PShepII purification in Method II PShepII HEP Puri- Puri- Total Total enzyme Total Specific fi- fication volume protein activity activity activity cation Yield step (ml) (mg) (IU/ml) (IU) (IU/mg) ratio (%) Crude 461.00 231.71 0.48 220.12 0.95 / / enzyme Precipi- 415.00 144.93 0.51 211.6 1.46 1.54 96.13 tation of ammo- nium sulfate Q 99.00 18.11 0.45 40.00 2.21 2.33 18.17 Column CS-I 31.00 3.88 0.52 16.00 4.12 4.34 7.27 Column CS-II 1.00 1.94 0.64 14.00 7.20 7.58 6.36 Column

Example 3: Characterization of Heparinase PShepI and PShepII

(42) The molecular weight of PShepI was approximately 74700 Da as determined by SDS-PAGE. The exact molecular weight of PShepI was 74791 Da as determined by MALDI-TOF-MS mass spectrometry. The isoelectric point of PShepI was 7.77 as determined by isoelectric focusing electrophoresis.

(43) The molecular weight of PShepII was about 94000 Da as determined by SDS-PAGE, and the exact molecular weight was 94716 Da as determined by MALDI-TOF-MS mass spectrometry. The isoelectric point of PShepII was 5.76 as determined by isoelectric focusing electrophoresis.

(44) The heparan sulfate (HS) substrate was dissolved in a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer to prepare a heparan sulfate solution at a concentration of 1 mg/mL. The concentration of heparan sulfate substrate was set to 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 mg/mL, respectively, and the activity of the enzyme at various heparan sulfate substrate concentrations was measured to calculate the Michaelis constant of the enzyme for heparan sulfate.

(45) The heparin (HEP) substrate was dissolved in a 25 mM Tris-HCl (containing 10 mM CaCl.sub.2, pH 7.0) buffer to prepare a heparin solution at a concentration of 1 mg/mL. The concentration of heparin substrate was set to 0.01, 0.03, 0.05, 0.1, 0.2, 0.4, 0.5, 0.6, 0.8, 1.0 mg/mL, respectively, and the activity of the enzyme at various heparin substrate concentrations was measured to calculate the Michaelis constant of the enzyme for heparin. The initial rate of the enzyme reaction under each condition was determined at different substrate concentrations to determine the Michaelis constant.

(46) It was determined that the Michaelis constants of PShepI were 4.20 and 0.28, respectively, when HEP and HS were used as substrates. It was determined that the Michaelis constants of PShepII were 0.09 and 0.25, respectively, when HEP and HS were used as substrates.

Example 4: Substrate Specificity and Product Specificity of PShepI and PShepII

(47) Study on substrate specificity of PShepI: Activity of PShepI was determined using heparin (HEP), heparan sulfate (HS), chondroitin sulfate (CS), and dermatan sulfate (DS) as substrates respectively. It was found that PShepI had no enzymatic activity when CS and DS were used as substrates, but had enzymatic activity when HEP and HS were used as substrates, and the activity ratio was about HEP:HS=0.87:1.

(48) Study on substrate specificity of PShepII: Activity of PShepII was determined using heparin (HEP), heparan sulfate (HS), chondroitin sulfate (CS), and dermatan sulfate (DS) as substrates respectively. It was found that the PShepII enzyme had no enzymatic activity when CS and DS were used as substrates, but had enzymatic activity when HEP and HS were used as substrates, and the activity ratio was about HEP:HS=1:4.3.

(49) Disaccharide analysis on PShepI enzymatic hydrolysis of HEP: 3 IU (heparin-based enzyme activity) of PShepI was added to 50 mg heparin, and made up with 25 mM Tris-HCl (containing 10 mM CaCl.sub.2), pH 7.0) buffer to 500 l, 37 C. for 24 h for enzymatic hydrolysis, then placed in a 100 C. water bath for inactivattion for 5 minutes, and then liquid phase analysis was carried out for the disaccharide component of the sample. The results are shown in FIG. 2. After enzymatic hydrolysis of HEP by PShepI, the main disaccharide components of the product were IIS and IS, where the peak area of IS accounted for 67.92%.

Example 5: Sequencing of Heparinase PShepI

(50) The genomic DNA of the Z7 Pseudomonas stutzeri strain was extracted by using the TIANamp Bacteria DNA Kit Bacterial Genomic DNA Extraction Kit according to the instructions of the kit. Thereafter, the extracted genomic DNA of the Z7 Pseudomonas stutzeri strain was sequenced to obtain the genome sequence of the Z7 Pseudomonas stutzeri strain.

(51) The PShep I enzyme isolated and purified from the Z7 Pseudomonas stutzeri was subjected to in-gel digestion by Kumarathan method (K method for short), followed by MALDI analysis to obtain a peptide spectrum of the heparinase PShepI. The protein sequence information obtained by the peptide spectrum is aligned with the ORF obtained from the genomic sequence of the Z7 strain, to finally obtain the coding sequence (1971 bp, SEQ ID NO:1) and the amino acid sequence (656 amino acid residues, SEQ ID NO:2) of PShepI.

Example 6: Preparation of PShepI Engineered Bacterium

(52) In order to further increase the yield of PShep I (the enzyme yield of the Z7 strain was about 150 IU/L), the inventors performed codon optimization to the coding sequence of PShepI according to the codon preference of E. coli BL21 (DE3), and added a 6His tag (SEQ ID NO: 3) to the N-terminus of the PShep I enzyme. The corresponding coding sequence was cloned into the pET-30a vector and then transformed into the E. coli BL21 (DE3) strain to obtain an engineered strain. The engineered bacterium was fermented to obtain an engineered enzyme with a yield of up to about 10000 IU/L (the yield of the Z7 strain was about 150 IU/L). The 232 nm endpoint absorbance value, molecular weight, potency and yield in hydrolyzing heparin of the engineered enzyme and the wildtype enzyme were consistent, and thus it was confirmed that the engineered enzyme and the wildtype enzyme had substantially the same properties.